Activated Partial Thromboplastin Time Test Market Anticipated for Progressive CAGR Growth During 2020-2027

The global activated partial thromboplastin time test market forecast will surpass $601.2 million by the end of 2026, at a CAGR of 6.8%, and has been rising from $353.0 million in 2018, according to Activated Partial Thromboplastin Time Test Market Analysis by Research Dive.

Activated Partial Thromboplastin Time Test Market Trends: Rise in the prevalence of cardiovascular diseases coupled with increase in the demand for thromboplastin test instruments the key drivers for the growth of the activated partial thromboplastin time test market Increase in the adoption of thromboplastin test in the point-of-care diagnostic centers and improvements in the healthcare infrastructure are projected to drive the market growth. The improvements in healthcare infrastructure support the accessibility of test instruments and easy available of coagulation testing devices is anticipated to boost the activated partial thromboplastin time (APTT) test market growth. Furthermore, there is a rise in the blood disorders with increasing age of people across the globe; they require regular blood check-up to determine common and intrinsic pathways of blood coagulation. Due to wide usage of APTT test devices, the market is projected to grow in the coming years. Price of the treatment test coupled with dearth of skilled personal to perform APTT test are expected to hinder the growth of the market. Technological improvements in the activated partial thromboplastin time (APTT) testing instruments and key manufacturers concentrating on mergers & acquisitions to minimize the devices cost is anticipated to create ample investment opportunities in the activated partial thromboplastin time test market.

Download FREE Sample Copy of the Report at: https://www.researchdive.com/download-sample/79

Instruments type segment will witness a noteworthy growth during the projected time. The growth is majorly because companies are increasing the R&D activities on diagnostic instruments to improve performance and accuracy of the instruments with low cost. The activated partial thromboplastin time test market for instruments product type is estimated to account for $289.8 million by 2026 at a 7.2% CAGR.

The market for point-of-care testing is projected to experience significant growth; it is anticipated to generate a revenue of $83.6 million by 2026 and is growing at a 7.7% CAGR. This growth is because of an increase in the number of point-of-care testing centers along with an increase in the population with age group above 60. The hospitals segment held the largest activated partial thromboplastin time test market size in 2018; it is estimated to reach $217.6 million by 2026, increasing at a growth rate of 6.5%. This is because of the growing usage of thromboplastin time test devices in the hospitals sector to treat patients for the analysis of hematological.

Asia-Pacific market will witness the highest growth rate of 7.3% CAGR and is expected to register a revenue of $143.1 million by 2026. This growth is attributed to swift progress in healthcare along with people preferring the point of care diagnosis of hospitals. Due to this swift growth, the Asia-Pacific market is predicted to grow during the forecast time. The global activated partial thromboplastin time test market was dominated by Europe, it was registered for majority of the activated partial thromboplastin market share, which was 30.0% in 2018. This growth is owing to the presence of upgraded diagnostic infrastructure in Europe. The market for North America region is expected to generate a revenue of $156.3 million by the end of 2026 with a CAGR of 6.7% during the projected time period.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/79

Top gaining participants in the activated partial thromboplastin time test market are Bio-Rad Laboratories, Inc., ThermoFisher, Abbott, bioMérieux, Inc., Danaher, Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Takara Bio Inc., HORIBA, Ltd., Ortho Clinical Diagnostics and Siemens Healthcare Private Limited. These participants are continuously increasing their efforts to improve the product performance and introducing new technologies to gain the largest market share in the overall activated partial thromboplastin time test industry.

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
Free : +1 -888-961-4454
Email: support@researchdive.com
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://covid-19-market-insights.blogspot.com

COVID-19 Impact: What Challenges Critical Care Devices Market May See In Next 5 Years?

The coronavirus outbreak has influenced the critical care devices industry fairly and positively. Expanded usage of critical care devices is expected to fuel the demand for COVID-19 care during the forecast era. Markets are projected to provide investors with more growth prospects over time. Leading players of the market are predicted to unlock vibrant opportunities for the growth of the market in the forthcoming years by taking various initiatives. The latest research report on the global critical care devices market by Research Dive reflects the influence of COVID-19 pandemic on the present and expected growth of the global market. This report is professional and comprehensive research formulated by specialists by evaluating top driving factors, major regional market situations, opportunities & future scope, and trends & developments in the market during the COVID-19 catastrophe. For More Detail Insights, Download FREE Sample at: https://www.researchdive.co...

What are the Left Atrial Appendage Closure Devices Market Key Insights and COVID-19 Business Impact?

Download FREE Sample Connect with Analyst The COVID-19 outbreak has significantly affected the global left atrial appendage closure devices market. As per American Heart Association, people having high blood pressure, heart valve disease and congenital heart diseases are expected to develop severe coronavirus symptoms. Also, this virus can generate heart strokes through weakening of muscles of the heart. These fators will boost the demand for left atrial appendage closure divices and surge the market growth during the pandemic. Furthermore, the leading manufactures in the global market are adopting various strategies such as product innovations and partnerships to increase their market share in the overall industry. For example, in July 2020, Boston Scientific Corporation announced that the “Watchman FLX left atrial appendage closure device” has been approved by U.S. Food and Drug Administration, which is used to minimize the threat of heart stroke in patients. The stroke r...

GLOBAL FLUOROETHYLENE CARBONATE(FEC) INDUSTRY: HUGE GROWTH OPPORTUNITIES, FORECAST TO 2025

The evaluation of the various elements of the global Fluoroethylene Carbonate(FEC) Industry dynamics is highly sought after by stakeholders of all types and entrepreneurs planning to make a foray into the market. The study on the global Fluoroethylene Carbonate(FEC) Industry is prepared with the help of several rounds of primary research and a vast spectrum of secondary research . The application of industry-wide statistical methods to the large amount of data generated further ads credibility to the analyses. The study on the global and regional Fluoroethylene Carbonate(FEC) Industry dynamics is a crucial guide to all those stakeholders, especially regulatory agencies and policy makers . Summary of Market: The global Fluoroethylene Carbonate(FEC) Industry is valued at xx million US$ in 2019 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025 . This report focuses on Fluoroethylene Carbonate(FEC) Industry volume and value at global ...

MyTrade-Insights

Search This Blog